Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 10, 2007

Panacos Extends Medicinal Chemistry Contract with Evotec Into Fourth Year

  • Panacos Pharmaceuticals extended its discovery collaboration with Evotec into its fourth year. Applying its expertise in medicinal chemistry, Evotec has been identifying compounds for treating viral infection.

    The work program has been expanded to include Evotec's development chemistry services. This development support includes the scale-up of selected compounds for development studies and the optimization of compounds prior to their selection for clinical studies through experiments such as salt screens.

    "Evotec's scientific expertise and project management skills are truly world-class," remarks Graham Allaway, Ph.D., CEO and president of Panacos. "Based on their excellent track record in moving compounds through discovery and into development, we decided to broaden the scope of our work with them. We are looking forward to continuing our productive relationship."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »